Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2,Open-label,Multicenter,Randomized Study of PD0332991 (Oral CDK4/6 Inhibitor) Monotherapy and in Combination With the HT to Which the pt Has Progressed in the Previous Line for ER+,Her2- Post-menopausal Advanced Breast Cancer Pts

NCT02549430 is registered in ClinicalTrials.gov with Fondazione Sandro Pitigliani as lead sponsor.

NCT NCT02549430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02549430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2,Open-label,Multicenter,Randomized Study of PD0332991 (Oral CDK4/6 Inhibitor) Monotherapy and in Combination With the HT to Which the pt Has Progressed in the Previous Line for ER+,Her2- Post-menopausal Advanced Breast Cancer Pts
Lead sponsor
Fondazione Sandro Pitigliani
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2012
Completion date
February 9, 2017
Enrollment
115 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer